Targeting the endocannabinoid system: to enhance or reduce?

Key Findings:  Cannabinoid-based therapeutics that increase or decrease the bioavailability of endocannabinoids may offer novel treatment options for pain, mood disorders, neurodegenerative disorders, gastrointestinal inflammatory disorders, obesity, metabolic disorders, cardiovascular conditions and liver diseases for example. However, the authors also suggest that more research is needed to determine optimal or future therapeutic use.

Type of Study:  Meta-analysis

Study Result:  Positive

Cannabinoids Studied:  Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Cannabinoid (unspecified)

Phytocannabinoid Source:  Not Applicable

Form of Administration:  Not Applicable

Receptors Studied:  CB1, CB2, Not Applicable

Study Location(s):  Italy

Year of Pub:  2008

Link to study